Literature DB >> 3058614

Long-term (5-year) results after either horizontal gastroplasty or very-low-calorie diet for morbid obesity.

T Andersen1, K H Stokholm, O G Backer, F Quaade.   

Abstract

Fifty-seven patients allocated at random to either diet supported by gastroplasty or very-low-calorie diet (VLCD) were followed for 5 years. One patient was lost to follow-up 1 year after surgery. Data were analyzed by survival statistics and success was liberally defined as a maintained weight loss of at least 10 kg. The cumulative success rate declined steadily in both groups, but it remained higher in the gastroplasty group (16 versus 3 percent, the 95 percent confidence limits being 11-21 percent and 1-5 percent, respectively; P less than 0.05). At 5 years, eight of 27 gastroplasty patients (30 percent, 95 percent confidence limits 14-50 percent) had not relapsed. Of 30 VLCD patients, relapse had not occurred in five (17 percent, 6-35 percent). The weight loss of patients without relapse did not differ significantly (medians of gastroplasty and VLCD patients 18 kg and 27 kg, respectively). Complications and side-effects were more numerous and serious among the gastroplasty patients. Although in this long-term study, the horizontal gastroplasty proved to be somewhat more effective than the diet alone, the surgical risks and the unsatisfactory maintenance of weight loss speak against the use of this operation.

Entities:  

Mesh:

Year:  1988        PMID: 3058614

Source DB:  PubMed          Journal:  Int J Obes


  15 in total

Review 1.  Effective management of obesity.

Authors:  S O'Meara; A M Glenny; C Wilson; A Melville; T A Sheldon
Journal:  Qual Health Care       Date:  1997-09

2.  Interdisciplinary European guidelines for surgery for severe (morbid) obesity.

Authors:  Martin Fried; Vojtech Hainer; Arnaud Basdevant; Henry Buchwald; Mervyn Deitel; Nicholas Finer; Jan Willem M Greve; Fritz Horber; Elisabeth Mathus-Vliegen; Nicola Scopinaro; Rudolf Steffen; Constantine Tsigos; Rudolf Weiner; Kurt Widhalm
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

3.  Interdisciplinary European guidelines on metabolic and bariatric surgery.

Authors:  M Fried; V Yumuk; J M Oppert; N Scopinaro; A Torres; R Weiner; Y Yashkov; G Frühbeck
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

Review 4.  Randomized controlled trials in bariatric surgery.

Authors:  Chien-Pin Chan; Bing-Yen Wang; Ching-Yuan Cheng; Ching-Hsiung Lin; Ming-Chia Hsieh; Jun-Jiun Tsou; Wei-Jei Lee
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

Review 5.  Morbid Obesity as a Therapeutic Target for Heart Failure.

Authors:  Chonyang L Albert
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-05

Review 6.  Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care.

Authors:  J D Douketis; J W Feightner; J Attia; W F Feldman
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

Review 7.  Surgical intervention as a strategy for treatment of obesity.

Authors:  L Sjöström
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.633

8.  Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES).

Authors:  S Sauerland; L Angrisani; M Belachew; J M Chevallier; F Favretti; N Finer; A Fingerhut; M Garcia Caballero; J A Guisado Macias; R Mittermair; M Morino; S Msika; F Rubino; R Tacchino; R Weiner; E A M Neugebauer
Journal:  Surg Endosc       Date:  2004-12-02       Impact factor: 4.584

9.  Long-term effects of a ketogenic diet in obese patients.

Authors:  Hussein M Dashti; Thazhumpal C Mathew; Talib Hussein; Sami K Asfar; Abdulla Behbahani; Mousa A Khoursheed; Hilal M Al-Sayer; Yousef Y Bo-Abbas; Naji S Al-Zaid
Journal:  Exp Clin Cardiol       Date:  2004

Review 10.  Sweeteners and health: findings from recent research and their impact on obesity and related metabolic conditions.

Authors:  J M Rippe; L Tappy
Journal:  Int J Obes (Lond)       Date:  2016-03       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.